Frazier Life Sciences Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Frazier Life Sciences Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,025	Closed	-$29.7K	–	53
2023 Q1	$29.7K	Hold	17,025	–	–	﹤0.01%	49
2022 Q4	$32.2K	Hold	17,025	–	–	﹤0.01%	44
2022 Q3	$35K	Sell	17,025 -1	-0%	-$4	﹤0.01%	43
2022 Q2	$77K	Hold	17,026	–	–	0.01%	41
2022 Q1	$179K	Buy	+17,026	New	+$207K	0.02%	42

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Addison Advisors Middlebury, Vermont $212M AUM 18.02% 1-Year Est. Return

Frazier Life Sciences Management's NBRV Position: Q2 2023 in Review

Frazier Life Sciences Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2023, closing a stake of 17,025 shares — an estimated $29.7K sold.

Frazier Life Sciences Management first reported a position in NBRV in Q1 2022 and held it in 5 quarters. The position peaked at $179K in Q1 2022. 9 funds tracked by Wall St. Rank hold NBRV as of Q2 2023.

Frazier Life Sciences Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2023 after selling out during the quarter.
Frazier Life Sciences Management sold 17,025 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2023, an estimated $29.7K.
Frazier Life Sciences Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2022 and held it in 5 quarters.
Frazier Life Sciences Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $179K in Q1 2022.
9 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2023.

Based on Frazier Life Sciences Management's 13F filing for Q2 2023, filed 14 Aug 2023.